高cTnI与心血管事件风险:macrotroponins的影响
Macrotroponins One Reason Not to Take cTnI Readings at Face Value
一项挪威队列研究发现,高cTnI(>10 ng/L)但无macrotroponins时,心血管事件风险显著升高;而高cTnI伴macrotroponins则风险较低,与cTnI<5 ng/L相似。研究提示在解读cTnI结果时需考虑macrotroponins的存在。
研究揭示了高cTnI与心血管事件风险的关系,强调了macrotroponins的存在对风险评估的影响。
— High cTnI less of a red flag when macro-cTnI is also in the picture
by Nicole Lou, Senior Staff Writer, MedPage Today
November 17, 2026 • 3 min read
- A Norwegian cohort study analyzed the the association between cardiac troponin (cTn) I and incident cardiovascular events in the general population.
- cTnI > 10 ng/L in the absence of macro-cTnI was associated with markedly high risk of cardiovascular events.
- cTnI >10 ng/L plus macro-cTnI present, on the other hand, was associated with risk comparable to cTnI <5 ng/L.
Beware attempts to interpret cardiac troponin (cTn) as a cardiovascular risk marker without accounting for the presence of macrotroponins, researchers warned.
In a cohort study of community dwellers in Norway, high cardiac troponin I (cTnI; >10 ng/L) without any macro-cTnI was associated with a whopping 50.0% rate of incident cardiovascular events over a median follow-up of 8.3 years, according to a group led by Torbjørn Omland, MD, MPH, of University of Oslo and Akershus University Hospital in Lørenskog, Norway.
This was a significant jump in cardiovascular risk compared to those with high cTnI and prevalent macro-cTnI (6.8%; adjusted HR 8.5, 95% CI 3.1-23.6) or those whose cTnI readings were deemed too low to merit additional macro-cTnI testing (7.2% in the group with cTnI <5 ng/L; adjusted HR 6.1, 95% CI 3.2-11.6).
"The salient novel findings of the current population-based study are that macro-cTnI is highly prevalent in individuals in the general population with cTnI >10 ng/L by the widely used Abbott high-sensitivity assay and that macrotroponin presence may obscure the true association between cTnI and the incidence of cardiovascular events," Omland and colleagues reported in European Heart Journal.
Macrotroponins are high-molecular-weight complexes formed by cTn autoantibodies and circulating cTn molecules. These large complexes are slower to clear than cTn alone, which can cause assays to read higher.
With macrotroponin I apparently more prevalent than macrotroponin T, study authors suggested implications for interpreting cTnI results in real-world practice.
"Despite the consistent high prognostic value of cTnI demonstrated in numerous studies and individual participant meta-analyses, misclassification of risk based on high concentrations due to the presence of cTnI autoantibodies has been recognized as a potential problem. The current findings suggest that accounting for the presence of macro-cTnI may enhance the prognostic value of cTnI by reducing the extent of risk misclassification," they wrote.
Omland's team based the study on 3,703 community dwellers (median age 64 years, 49% women) participating in the Akershus Cardiac Examination 1950 Study.
Serum cTnI was initially analyzed using the ARCHITECT STAT high-sensitivity (hs) assay; the same samples were used to measure cTnT on a Cobas e801 using the STAT hs-troponin T assay. Investigators then sought samples where cTnI exceeded 10 ng/L (approximately corresponding to the study-specific 95th percentile) for subsequent detection of macro-cTnI.
Out of 108 people with such high cTnI, 81% met criteria for having macro-cTnI. Participants with original cTnI concentration <5 ng/L (n=3,256) or 5-10 ng/L (n=267) were the control groups.
The investigators found that people with high cTnI and prevalent macro-cTnI tended to have lower cTnT concentrations (9.0 vs 19.0 ng/L without macro-cTnI, P<0.001).
Beyond that, there were no significant between-group differences for age, sex, kidney function, C-reactive protein concentrations, use of cardioactive medications, prior cardiovascular disease, or risk factors at baseline.
The study's primary endpoint covered a composite of myocardial infarction, ischemic stroke, heart failure, coronary revascularization, and cardiovascular mortality.
Compared with people with cTnI levels under 5 ng/L, those with a high cTnI and macro-cTnI turned out not to be at significantly greater cardiovascular risk (7.2% vs 6.8%; adjusted HR 0.7, 95% CI 0.3-1.6).
Study authors cautioned that the study was limited by the complexity of the macrotroponin detection method used and the moderate number of participants with cTnI >10 ng/L, among other caveats.
"It remains unknown whether assay interference or delayed clearance of macrotroponin causes higher cTnI levels in those classified as macro-cTnI positive," Omland and colleagues added. "As such, these observations should be regarded as preliminary and hypothesis-generating, requiring validation in larger, more diverse, and higher-risk study populations."
来源:MedPage Today · medpagetoday.com